Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Highly potent H3 receptor antagonist with potential therapeutic use

Nov. 5, 1998

Chinese researchers report that synthetic calcium antagonist improves memory dysfunction

Nov. 5, 1998

Angiotech study of micellar paclitaxel in MS well under way

Nov. 5, 1998

Bayer announces setback in AD drug development

Nov. 5, 1998

New sigma-receptor ligands presented by Sumitomo

Nov. 5, 1998

GlyT-1 technology forms the basis of Allelix and Janssen neuropsychiatric collaboration

Nov. 4, 1998

Meiji Seika discloses new neuroprotective substance isolated from fungus

Nov. 4, 1998

Novel isoquinoline anticonvulsants in development at SB

Nov. 4, 1998

Entropin concentrates its efforts on bringing Esterom to market

Nov. 4, 1998

Monoamine reuptake inhibitors especially useful for Parkinson's disease

Nov. 3, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 13, 2026.
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...